Last reviewed · How we verify
Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (alleviate 1)
The trial is conducted in Asia, Europe and North America. The aim of the study is to evaluate the safety of administration under the skin of turoctocog alfa pegol (SC N8-GP) in patients with severe haemophilia A.
Details
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 50 |
| Start date | Mon Jan 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Oct 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Congenital Bleeding Disorder
- Haemophilia A
Interventions
- turoctocog alfa pegol
Countries
France, Japan, Serbia, Austria, Germany, United States